DIRECT HIRE - Applied Therapeutics, Inc. - Regional Account Manager - Rare Disease - New England Territory
Job Description
The Regional Account Manager is responsible for growing sales volume and market share of Applied Therapeutics, Inc.’s products within a specified geographic territory through business plans and execution that align with direction from commercial leadership and with all company guidelines, policies, and directives.
ESSENTIAL DUTIES AND RESPONSIBILITIES:
Our employees are tasked with delivering excellent business results through their passion for patients. Duties may include, but are not limited to:
Reasonable accommodation may be made to enable individuals with disabilities to perform the essential functions of this position.
#LI-LH1
Qualifications
MINIMUM KNOWLEDGE, SKILLS AND ABILITIES:
The requirements listed below are representative of the experience, education, knowledge, skill and/or abilities required.
Additional Information
At Applied Therapeutics, Inc., we are passionate about our mission to create transformative, life-changing treatments for patients with fatal or debilitating diseases with no approved therapies who desperately need them. We target pathways with known roles in pathogenesis and develop novel compounds with improved potency and selectivity. Our lead product candidate, govorestat (also called AT-007), is an investigational, novel Aldose Reductase Inhibitor (ARI) being developed for the treatment of several rare diseases, including Galactosemia, SORD Deficiency and PMM2-CDG. Govorestat is a potent and selective compound, which crosses the blood brain barrier into the Central Nervous System (CNS penetrant) that has received Orphan Medicinal Product Designation from the EMA, and both Orphan Drug and Pediatric Rare Disease designations from the FDA for the treatment of Galactosemia, a rare metabolic disease, and PMM2-CDG. A New Drug Application (NDA) for govorestat has been accepted for priority review with the FDA and the Marketing Authorization Application (MAA) has been validated and is currently being reviewed by the EMA’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of Galactosemia. Additionally, govorestat is currently in pivotal-stage development for the treatment of SORD Deficiency.
EVERSANA is supporting Applied Therapeutics, Inc. in the recruitment for this role.